BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses 2020;12:E126. [PMID: 31973017 DOI: 10.3390/v12020126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Peyret H, Steele JFC, Jung JW, Thuenemann EC, Meshcheriakova Y, Lomonossoff GP. Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult. Vaccines (Basel) 2021;9:780. [PMID: 34358196 DOI: 10.3390/vaccines9070780] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ye H, Teng J, Lin Z, Wang Y, Fu X. Analysis of HBsAg mutations in the 25 years after the implementation of the hepatitis B vaccination plan in China. Virus Genes 2020;56:546-56. [PMID: 32542478 DOI: 10.1007/s11262-020-01773-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gerlich WH. [Hepatitis B vaccines-history, achievements, challenges, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015108 DOI: 10.1007/s00103-021-03484-w] [Reference Citation Analysis]
4 Markarian NM, Abrahamyan L. AMDV Vaccine: Challenges and Perspectives. Viruses 2021;13:1833. [PMID: 34578415 DOI: 10.3390/v13091833] [Reference Citation Analysis]
5 Erken R, Zaaijer HL, Willemse SB, Bakker E, Takkenberg BB, Reesink HW, Kootstra NA. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol 2021;26:100540. [PMID: 34583061 DOI: 10.1016/j.aohep.2021.100540] [Reference Citation Analysis]
6 Vogel M, Bachmann MF. Special Issue "Virus-Like Particle Vaccines". Viruses 2020;12:E872. [PMID: 32784958 DOI: 10.3390/v12080872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zinkhan S, Ogrina A, Balke I, Reseviča G, Zeltins A, de Brot S, Lipp C, Chang X, Zha L, Vogel M, Bachmann MF, Mohsen MO. The impact of size on particle drainage dynamics and antibody response. J Control Release 2021;331:296-308. [PMID: 33450322 DOI: 10.1016/j.jconrel.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Reference Citation Analysis]
9 Butkovich N, Li E, Ramirez A, Burkhardt AM, Wang SW. Advancements in protein nanoparticle vaccine platforms to combat infectious disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1681. [PMID: 33164326 DOI: 10.1002/wnan.1681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Yato K, Onodera T, Matsuda M, Moriyama S, Fujimoto A, Watashi K, Aizaki H, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Tamura K, Takahashi Y, Wakita T, Muramatsu M, Kato T, Suzuki R. Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1. J Virol 2020:JVI. [PMID: 33298539 DOI: 10.1128/JVI.01680-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Mohsin DH, Mashkour MS, Fatemi F. Design of aptamer-based sensing platform using gold nanoparticles functionalized reduced graphene oxide for ultrasensitive detection of Hepatitis B virus. Chem Pap 2021;75:279-95. [DOI: 10.1007/s11696-020-01292-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
12 Cortese MF, Riveiro-Barciela M, Tabernero D, Rodriguez-Algarra F, Palom A, Sopena S, Rando-Segura A, Roade L, Kuchta A, Ferrer-Costa R, Quer J, Pacin B, Vila M, Casillas R, Garcia-Garcia S, Esteban R, Pumarola T, Buti M, Rodriguez-Frias F. Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. Microbiol Spectr 2022;:e0214921. [PMID: 35377229 DOI: 10.1128/spectrum.02149-21] [Reference Citation Analysis]
13 Deshpande MS, Banerjee T. A decoy strategy to activate the immune system. IUBMB Life 2021;73:1205-9. [PMID: 34455696 DOI: 10.1002/iub.2548] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses 2020;12:E488. [PMID: 32349216 DOI: 10.3390/v12050488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Konopleva MV, Borisova VN, Sokolova MV, Semenenko TA, Suslov AP. Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro. Vaccines 2022;10:235. [DOI: 10.3390/vaccines10020235] [Reference Citation Analysis]
16 Comas-Garcia M, Colunga-Saucedo M, Rosales-Mendoza S. The Role of Virus-Like Particles in Medical Biotechnology. Mol Pharm 2020;17:4407-20. [PMID: 33147978 DOI: 10.1021/acs.molpharmaceut.0c00828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Khavinson V, Terekhov A, Kormilets D, Maryanovich A. Homology between SARS CoV-2 and human proteins. Sci Rep 2021;11:17199. [PMID: 34433832 DOI: 10.1038/s41598-021-96233-7] [Reference Citation Analysis]
19 Marfe G, Perna S, Shukla AK. Effectiveness of COVID-19 vaccines and their challenges (Review). Exp Ther Med 2021;22:1407. [PMID: 34676000 DOI: 10.3892/etm.2021.10843] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gao T, Gao C, Wu S, Wang Y, Yin J, Li Y, Zeng W, Bergmann SM, Wang Q. Recombinant Baculovirus-Produced Grass Carp Reovirus Virus-Like Particles as Vaccine Candidate That Provides Protective Immunity against GCRV Genotype II Infection in Grass Carp. Vaccines (Basel) 2021;9:53. [PMID: 33466933 DOI: 10.3390/vaccines9010053] [Reference Citation Analysis]
21 Hirota M, Takahashi H, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Eguchi H, Doki Y, Nakajima K. Surgical plume from tissue infected with human hepatitis B virus can contain viral substances. Minim Invasive Ther Allied Technol 2021;:1-9. [PMID: 33853487 DOI: 10.1080/13645706.2021.1910848] [Reference Citation Analysis]
22 Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Reference Citation Analysis]
23 Joe CCD, Chatterjee S, Lovrecz G, Adams TE, Thaysen-Andersen M, Walsh R, Locarnini SA, Smooker P, Netter HJ. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity. Vaccine 2020;38:3892-901. [PMID: 32284273 DOI: 10.1016/j.vaccine.2020.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]